在本論文中，我們合成八個具有4-硝基咪唑或2-硝基咪唑之木酚素衍生物，以作為抗肝癌之先導藥物。其中四個具有polyethyl glycol之化合物可增加其水溶性。這些硝基咪唑之木酚素衍生物經由生物活性測試，在提供20%氧氣與缺氧的條件下對於肝癌細胞Hep3B之IC50介於10–20 μM。

Eight methylated nordihydroguaiaretic acids containing a 4- or 2-nitroimidazole moiety were synthesized as leads against hepatocellular carcinoma. Four of these conjugated compounds possessing a polyethylene glycol tether for improvement of their aqueous solubility. These nordihydroguaiaretic acid–nitroimidazole conjugates were found to inhibit hepatocellular carcinoma Hep3B cells under 20% oxygen and hypoxia conditions with IC50 values between 10–20 μM

1. Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., de Oliveira, A. C., Santoro, A., Raoul, J. L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T. F., Galle, P. R., Seitz, J. F., Borbath, I., Haussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D., and Bruix, J. (2008) N. Engl. J. Med. 359, 378–390
2. (a) Ma, S., Chan, K. W., and Guan, X. Y. (2008) Stem Cell Rev. 4, 179–192 (b) Jemal, A., Siegel, R., Ward, E., Hao, Y. P., Xu, J. Q., Murray, T., and Thun, M. J. (2008) CA Cancer J. Clin. 58, 71–96
3. Bruix, J., and Llovet, J. M. (2002) Hepatology 35, 519–524
4. Boyer, S. H., Sun, Z. L., Jiang, H. J., Esterbrook, J., Gomez-Galeno, J. E., Craigo, W., Reddy, K. R., Ugarkar, B. G., MacKenna, D. A., and Erion, M. D. (2006) J. Med. Chem. 49, 7711–7720
5. Llovet, J. M., and Bruix, J. (2009) J. Clin. Oncol. 27, 833–835
6. Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., and Lynch, M. (2008) Mol. Cancer Ther. 7, 3129–3140
7. Wood, L. S. (2006) Commun. Oncol. 3, 558–562
8. Park, S. H., Lee, Y., Han, S. H., Kwon, S. Y., Kwon, O. S., Kim, S. S., Kim, J. H., Park, Y. H., Lee, J. N., Bang, S. M., Cho, E. K., Shin, B. D., and Lee, J. H. (2006) BMC Cancer 6
9. Gnabre, J. N., Ito, Y., Ma, Y., and Huang, R. C. (1996) J. Chromatogr. A 719, 353–364
10. Trang, T., Sutak, M., Quirion, R., and Jhamandas, K. (2003) Br. J. Pharmacol. 140, 295–304
11. Nakadate, T. (1989) Jpn. J. Pharmacol. 49, 1–9
12. Hausott, B., Greger, H., and Marian, B. (2003) J. Cancer Res. Clin. Oncol. 129, 569–576
13. Fujiwara, T., Misumi, Y., and Ikehara, Y. (2003) Biochem. Biophys. Res. Commun. 301, 927–933
14. Huang, J. K., Chen, W. C., Huang, C. J., Hsu, S. S., Chen, J. S., Cheng, H. H., Chang, H. T., Jiann, B. P., and Jan, C. R. (2004) Life Sci. 75, 2341–2351
15. Yamamura, H., Nagano, N., Hirano, M., Muraki, K., Watanabe, M., and Imaizumi, Y. (1999) J. Pharmacol. Exp. Ther. 291, 140–146
16. Ono, K., Hasegawa, K. U., Yoshiike, Y., Takashima, A., Yamada, M., and Naiki, H. (2002) J. Neurochem. 81, 434–440
17. Lee, C. H., Jang, Y. S., Her, S. J., Moon, Y. M., Baek, S. J., and Eling, T. (2003) Exp. Cell Res. 289, 335–341
18. Staal, F. J. T., Roederer, M., Raju, P. A., Anderson, M. T., Ela, S. W., and Herzenberg, L. A. (1993) AIDS Res. Hum. Retroviruses 9, 299–306
19. Chen, H. S., Teng, L., Li, J. N., Park, R., Mold, D. E., Gnabre, J., Hwu, J. R., Tseng, W. N., and Huang, R. C. C. (1998) J. Med. Chem. 41, 3001–3007
20. Gnabre, J. N., Brady, J. N., Clanton, D. J., Ito, Y., Dittmer, J., Bates, R. B., and Huang, R. C. C. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 11239–11243
21. Hwu, J. R., Tseng, W. N., Gnabre, J., Giza, P., and Huang, R. C. C. (1998) J. Med. Chem. 41, 2994–3000
22. Park, R., Giza, P. E., Mold, D. E., and Huang, R. C. C. (2003) Antiviral Res. 58, 35–45
23. Craigo, J., Callahan, M., Huang, R. C. C., and DeLucia, A. L. (2000) Antiviral Res. 47, 19–28
24. Park, R., Chang, C. C., Liang, Y. C., Chung, Y., Henry, R. A., Lin, E., Mold, D. E., and Huang, R. C. C. (2005) Clin. Cancer Res. 11, 4601–4609
25. Huang, R. C. C., Li, Y., Giza, P. E., Gnabre, J. N., Abd-Elazem, I. S., King, K. Y., and Hwu, J. R. (2003) Antiviral Res. 58, 57–64
26. Hwu, J. R., Hsu, M. H., and Huang, R. C. C. (2008) Bioorg. Med. Chem. Lett. 18, 1884–1888
27. Chang, C. C., Liang, Y. C., Klutz, A., Hsu, C. I., Lin, C. F., Mold, D. E., Chou, T. C., Lee, Y. C., and Huang, R. C. C. (2006) Cancer Chemother. Pharmacol. 58, 640–653
28. Heller, J. D., Kuo, J., Wu, T. C., Kast, W. M., and Huang, R. C. C. (2001) Cancer Res. 61, 5499–5504
29. Edwards, D. I. (1993) J. Antimicrob. Chemother. 31, 9–20
30. Ings, R. M. J., McFadzea, J. A., and Ormerod, W. E. (1974) Biochem. Pharmacol. 23, 1421–1429
31. Kizaka-Kondoh, S., Inoue, M., Harada, H., and Hiraoka, M. (2003) Cancer Sci. 94, 1021–1028
32. Shimamura, M., Nagasawa, H., Ashino, H., Yamamoto, Y., Hazato, T., Uto, Y., Hori, H., and Inayama, S. (2003) Br. J. Cancer 88, 307–313
33. Brown, J. M. (1999) Cancer Res. 59, 5863–5870
34. Teicher, B. A. (1994) Cancer Metastasis Rev. 13, 139–168
35. Lin, A. J., Sartorel.Ac, Shansky, C. W., and Cosby, L. A. (1972) J. Med. Chem. 15, 1247–1252
36. Takasawa, M., Moustafa, R. R., and Baron, J. C. (2008) Stroke 39, 1629–1637
37. Edwards, D. I. (1993) J. Antimicrob. Chemother. 31, 9–20
38. Chen, Y., and Hu, L. (2009) Med. Res. Rev. 29, 29–64
39. Lange, R. P., Locher, H. H., Wyss, P. C., and Then, R. L. (2007) Curr. Pharm. Des. 13, 3140–3154
40. Hwu, J. R., Lin, Y. S., Josephrajan, T., Hsu, M. H., Cheng, F. Y., Yeh, C. S., Su, W. C., and Shieh, D. B. (2009) J. Am. Chem. Soc. 131, 66–68
41. Veronese, F. M., and Mero, A. (2008) BioDrugs 22, 315–329
42. Hsu, M. H., Josephrajan, T., Yeh, C. S., Shieh, D. B., Su, W. C., and Hwu, J. R. (2007) Bioconjugate Chem. 18, 1709–1712
43. Reigan, P., Edwards, P. N., Gbaj, A., Cole, C., Barry, S. T., Page, K. M., Ashton, S. E., Luke, R. W. A., Douglas, K. T., Stratford, I. J., Jaffar, M., Bryce, R. A., and Freeman, S. (2005) J. Med. Chem. 48, 392–402
44. Mallia, M. B., Subramanian, S., Mathur, A., Sarma, H. D., Venkatesh, M., and Banerjee, S. (2008) Bioorg. Med. Chem. Lett. 18, 5233–5237
45. Scozzafava, A., Menabuoni, L., Mincione, F., and Supuran, C. T. (2002) J. Med. Chem. 45, 1466–1476